Aggressive Smoking Cessation Trial (ASAP)
NCT05257629
Recruiting
The ASAP Trial is a 5-year, multi-centre, randomized controlled trial that will assess the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk. It will recruit 798 adult patients smoking on average at least 10 conventional (tobacco) cigarettes per day who are motivated to quit smoking and have either been diagnosed with ACS requiring hospitalization or are outpatients at elevated cardiovascular risk. Patients will be randomized... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Fraser Clinical Trials, New Westminster, British Columbia +12 locations
Conditions: Acute Coronary Syndrome, Cardiovascular Diseases
Register for Updates
A Research Study to Collect Patient Reported Outcomes Using Electronic Surveys
NCT04990895
Recruiting
A single-centre, randomized, 2-arm clinical trial comparing follow-up consisting of tumour-specific Electronic Patient-Reported Outcomes (ePROs) with targeted symptom management versus standard of care follow-up during neoadjuvant/adjuvant systemic therapy
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2025
Locations: Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta
Conditions: Colorectal Cancer, Breast Cancer
Register for Updates
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
NCT06317441
Recruiting
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO). Two doses of probiotic will be evaluated against placebo.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/24/2025
Locations: Nimble Science, Calgary, Alberta
Conditions: Small Intestinal Bacterial Overgrowth, SIBO
Register for Updates
Treatment of the Biceps With Concomitant Supraspinatus Tears
NCT05660031
Recruiting
The long head of the biceps (LHB) tendon is thought to be a common source of shoulder pain and dysfunction in patients with rotator cuff pathology. Tenotomy and tenodesis have been shown to produce favourable and comparable results in treating LHB lesions, but a controversy still exists regarding the treatment of choice. Some suggest that tenotomy should be reserved for older, low-demand patients, while tenodesis should be performed in younger patients and those who engage in heavy labor. Propon... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
04/23/2025
Locations: Sports Medicine and Shoulder Surgery, University of Michigan, Ann Arbor, Michigan +3 locations
Conditions: Supraspinatus Tear
Register for Updates
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
NCT05407987
Recruiting
Iron deficiency has been reported in approximately 35% of patients with a gynecologic malignancy. Blood transfusions are known to be immunosuppressive and carry immediate and long-term risks. Pre-operative blood transfusion in gynecologic oncology patients is associated with higher rates of surgical site infection, length of stay, composite morbidity, cancer recurrence, and mortality. Pre-operative intravenous iron formulations have been shown in benign gynecology and other surgical specialities... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta
Conditions: Gynecologic Cancer, Anemia, Iron-deficiency
Register for Updates
Nabilone for Agitation Blinded Intervention Trial
NCT04516057
Recruiting
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms. Agitation is associated with faster progression to institutionalization, increased caregiver burden, poorer quality of life, and increased risk of death. In addition, current pharmacological options show only modest efficacy and elevated risks of adverse events... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/23/2025
Locations: University of Calgary, Calgary, Alberta +5 locations
Conditions: Alzheimer Disease, Agitation
Register for Updates
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression
NCT06853587
Recruiting
This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/23/2025
Locations: University of Calgary, Calgary, Alberta
Conditions: Anxiety and Depression
Register for Updates
Does Psilocybin Require Psychedelic Effects to Treat Depression?
NCT05710237
Recruiting
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. In healthy volunteers, the psychedelic effects of psilocybin have been shown to be blocked by administration of serotonin (5HT)2A receptor antagonists such as risperidone. The purpose of this "double dummy" proof-of-concept trial is to evaluate whether psilocybin's antidepressant effects are dependent o... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/23/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Treatment-resistant Depression
Register for Updates
HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers
NCT06487403
Recruiting
This is a single centre prospective exploratory study of effects of radiation therapy on biomarker development in patients with newly diagnosed (head and neck squamous cell carcinoma) HNSCC receiving curative therapy. This research is part 2 of the HN-BIO study.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Princess Margaret Cancer Centre, Toronto, Ontario
Conditions: Squamous Cell Carcinoma of Head and Neck
Register for Updates
A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632
Recruiting
Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. Treatments are available, but MM can come back (relapsed) or may not get better (refractory) with treatment. This is a study to determine adverse events and change in disease symptoms of ABBV-383 in adult participants with relapsed/refractory... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Mayo Clinic Arizona /ID# 251405, Phoenix, Arizona +40 locations
Conditions: Multiple Myeloma
Register for Updates
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +117 locations
Conditions: Progressive Pulmonary Fibrosis
Register for Updates
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)
NCT06518720
Recruiting
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to assess the feasibility, tolerability, and preliminary efficacy of psilocybin therapy for adults with chronic neuropathic pain and co-morbid treatment resistant depression.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/23/2025
Locations: Centre for Addiction and Mental Health, Toronto, Ontario
Conditions: Treatment Resistant Depression, Chronic Pain
Register for Updates